PharVision Advisers’s CleanSpark CLSK Stock Holding History

PharVision Advisers’s Portfolio CLSK Stock Details CLSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,027	Closed	-$243K	–	209
2025 Q4	$243K	Buy	+24,027	New	+$360K	0.12%	411
2025 Q2	–	Sell	-20,869	Closed	-$140K	–	294
2025 Q1	$140K	Buy	+20,869	New	+$198K	0.19%	229

Other funds holding CLSK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Situational Awareness San Francisco, California $13.7B AUM 334.5% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's CLSK Position: Q1 2026 in Review

PharVision Advisers sold out of CleanSpark (CLSK) in Q1 2026, closing a stake of 24,027 shares — an estimated $243K sold.

PharVision Advisers first reported a position in CLSK in Q1 2025 and held it in 2 quarters. The position peaked at $243K in Q4 2025. 352 funds tracked by Wall St. Rank hold CLSK as of Q1 2026.

PharVision Advisers reported no remaining CleanSpark position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 24,027 CleanSpark shares in Q1 2026, an estimated $243K.
PharVision Advisers first reported a position in CleanSpark in Q1 2025 and held it in 2 quarters.
PharVision Advisers's CleanSpark position peaked at $243K in Q4 2025.
352 funds tracked by Wall St. Rank held CleanSpark as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.